NEW YORK, June 23, 2015 /PRNewswire/ --
Promising drug pipeline and new entrants will widen targeted and immunotherapeutic treatment options, says GBI Research.
Analysis from business intelligence provider GBI Research - Non-Hodgkin Lymphoma Therapeutics in Major Developed Markets to 2020 - says that the Non-Hodgkin Lymphoma (NHL) treatment market will expand at a Compound Annual Growth Rate (CAGR) of 7.4%, from $5.6 billion in 2013 to more than $9 billion by 2020.
The marketed NHL products landscape comprises a wide range of treatment options, such as chemotherapies and combination, biologic, and targeted therapies. However, many patients suffer relapse or develop treatment resistance, meaning there is a need for safe and effective drugs that prolong the duration of remission and improve survival.
For a complimentary sample of this research, please visit the GBI Research website.
NHL accounts for approximately 5.1% of all cancers and 2.4% of all cancer-related deaths. It encompasses a heterogeneous group of malignancies that originate from lymphoid tissue, with varied clinical and biological features. While incidence is most prominent in developed countries, it is increasing in developing nations, although geographical distribution varies widely in terms of sub-types.
Analyst Shreya Brahmbhat: "While Rituxan (rituximab) has dramatically improved NHL patient prognosis and been the standard of care in front-line treatment regimens and maintenance settings, there is increasing evidence of rituximab resistance. This treatment challenge will create space for the entry of promising new therapies, which will ultimately drive NHL treatment market growth.
"The anticipated launch of third-generation, anti-CD20 monoclonal Antibody, obinutuzumab, may lead to stronger complement-dependent cytotoxicity in rituximab-resistant cell lines. Additionally, the immunotherapeutic vaccine dasiprotimut-T has the potential to eliminate the risk of rituximab resistance."
Key Findings Include:
- The US will have the largest NHL treatment market by 2020, worth $5.2 billion, due to rising disease incidence and increasing uptake of targeted and immunotherapies
- With 339 active pipeline molecules, most of the investigational drug candidates are being evaluated for first- or second-line NHL treatment, including novel mAbs, antibody-drug conjugates, radioimmunotherapies, small-molecule inhibitors, and various new chemotherapies
- However, analysis of clinical trials since 2006 has identified that NHL products have a high attrition rate
Click here to find out how this analysis could benefit your business.
About GBI Research
GBI Research is a leading provider of business intelligence reports, offering actionable data and forecasts based on the insights of key healthcare industry influencers to ensure you stay up-to-date with the latest market trends.
For the full range of market-leading analysis on the pharmaceutical industry, visit GBI Research's report store.
Follow GBI Research online for the latest healthcare industry updates:
For more information, please contact GBI Research on: +44-1204-543-533
SOURCE GBI Research